Search for: "Mylan Pharmaceuticals v. FDA" Results 121 - 140 of 233
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Jul 2011, 1:01 am by Marie Louise
KG (TTABlog) US: ALJ Rogers sets 17-month target date in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)   Products Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaints against APP Pharmaceuticals in Delaware and S D Indiana in response to Para IV certification filing (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of… [read post]
9 Mar 2011, 3:00 am by Marie Louise
Bayer AG  (FDA Law Blog) (Patent Docs) Dexilant (Dexlansoprazole) – US: Takeda files patent infringement suit against Handa following Para IV certification filing (Patent Docs) EpiPen – US: Orange Book patent delisting counterclaim raised in 505(b)(2) application patent infringement litigation; decision could provide guidance on drug delivery system patent listability: King Pharmaceuticals v Intelliject (FDA Law Blog) Fentora (Fentanyl)… [read post]
19 Apr 2011, 5:04 pm by Marie Louise
Highlights this week included: Aricept (Donepezil HCI) – US: Lawsuit alleges false marking based on Orange Book ‘advertising’: Pharmaceutical Technologies v Eisai (FDA Law Blog) (Patent Docs) Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
28 Sep 2016, 8:39 am by Dennis Crouch
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Mylan Pharmaceuticals, et al. v. [read post]
28 Jul 2010, 12:06 am by Kelly
Sanofi sues FDA over generic LOVENOX approval (FDA Law Blog) (FDA Law Blog) Lupron (Leuprolide) – US: False marking complaint filed concerning Lupron products: Promote Innovation LLC v. [read post]
6 Apr 2011, 12:18 am by Marie Louise
Highlights this week included: India firm on ‘NO’ to data exclusivity (SiNApSE) (Generic Pharmaceuticals and IP) (Spicy IP) (Spicy IP) US: CAFC hears oral arguments on patentability of DNA claims: American Molecular Pathology, et. al, v. [read post]
8 Feb 2011, 10:51 pm by Marie Louise
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court… [read post]
20 Jul 2011, 4:04 am by Marie Louise
: Supreme Court hearing Human Genome Sciences Inc v Eli Lilly and Company (IPKat) Nexium (Esomeprazole) – UK: EWHC: Ranbaxy wins declaration of non-infringement: Ranbaxy v AstraZeneca (IPKat) Olanzapine – Spain: Supreme Court hands down landmark judgment on doctrine of equivalents and TRIPS (Kluwer Patent Blog) OxyContin (Oxycodone) – US: Purdue files patent infringement suit against Sandoz in response to Para IV certification (Patent Docs) Prevacid (Lansoprazole)… [read post]
18 May 2011, 12:33 am by Marie Louise
Sun Pharmaceuticals on question of obviousness-type double patenting (Patent Docs) (IPBiz) Glumetza (Metformin) – US: Depomed receives notice of Para IV certification against patents from second ANDA filer, Sun Pharmaceutical (GenericsWeb) Myfortic7 (Mycophenolate) – US: Novartis files patent infringement complaint against Teva in response to Para IV certification filing (Patent Docs) NuvaRing (Etonogestrel, Estradiol) – US: ALJ Luckern sets procedural schedule in… [read post]
13 Jan 2010, 3:00 am
(IP Factor) Netherlands: Court of Appeal, The Hague: Costs of procedure : Lundbeck v Tiefenbacher, Centrafarm Services and Ratiopharm (EPLAW) Poland: First judgment on differences between sponsorship and advertising of pharmaceutical product (Class 46) US: USPTO to begin recalculating patent term following Wyeth v Kappos (Patently-O) (Patent Docs) US: CAFC confirms PTO is miscalculating (undercalculating) delays in prosecution and the corresponding patent term adjustment:… [read post]
16 May 2012, 12:22 pm by Bexis
Mylan Pharmaceuticals, Inc., ___ F. [read post]
27 Oct 2010, 3:38 am by Kelly
Abbott (EPLAW) Lunesta (Eszopiclone) – US: Cobalt Pharmaceuticals and Sepracor settle Lunesta patent litigation (Patent Docs) Mirapex (Pramipexole) – US: Mylan receives approval for generic version of Mirapex tablets (SmartBrief) Oracea (Doxycyline) – US: Mylan seeks declaratory judgment of non-infringement and invalidity based on ANDA filing: Mylan v Galderma (Patent Docs) Perlane, Restylane (Hyaluronic acid) – US: Genzyme files… [read post]
8 Jul 2010, 1:25 pm by FDABlog HPM
Court of Appeals for the Federal Circuit issued its April 2010 decision in Novo Nordisk A/S v. [read post]
23 Apr 2009, 10:00 pm
(Spicy IP) India: Assessing India’s innovation climate (Biotech Blog) Kenya’s anti-counterfeit legislation, India protest (Afro-IP) Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office) US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs) US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs)   Products Cepham… [read post]